For FLT3 inhibition we used Crenolanib (Creno), a promising drug shown to significantly increase the response rate, complete remission rate and relapse free survival of AML patients when combined with intensive chemotherapy (Wang et al. This evidence concerns the gene FLT3 and acute myeloid leukemia.